Search

Displaying results 4441 - 4450 of 10000 in total
  1. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    This is a novel therapeutic approach to treat kidney inflammation. … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.

  2. Drug

    Clomocycline

    go.drugbank.com/drugs/DB00453
    Experimental

    Clomocycline is a tetracycline used to treat bacterial infections.

  3. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

  4. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. … It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.

  5. Drug

    Ethacizine

    go.drugbank.com/drugs/DB13645
    Experimental

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ic
  6. Drug

    Dibutylphthalate

    go.drugbank.com/drugs/DB13716
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Gallium citrate

    go.drugbank.com/drugs/DB17893
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. … CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease.

  9. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  10. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.